Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aranesp coverage decision

Executive Summary

D.C. federal court dismisses Amgen's challenge of the Centers for Medicare & Medicaid Services' decision to reimburse Aranesp (darbepoetin) at the same level as Johnson & Johnson's Procrit (epoetin) under the final Hospital Outpatient Prospective Payment System rule for 2003. In a Dec. 26 1opinion, the court determined that Amgen lacked standing to challenge CMS from implementing certain provisions relating to Aranesp. CMS concluded that the two anemia therapies are "functionally equivalent" (2"The Pink Sheet" Nov. 4, p. 27)...

You may also be interested in...



Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule

The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.

Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head

Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel